TipRanks
Go Ultimate55% OFF

Generate Biomedicines, Inc. (GENB) Financial Statements

Generate Biomedicines, Inc. Financial Overview

Generate Biomedicines, Inc.'s market cap is currently $1.86B. The company's EPS TTM is $-1.06; its P/E ratio is -8.56; Generate Biomedicines, Inc. is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

Financial overview
Dec 25Dec 24
Income Statement
Total Revenue$ 31.89M$ 20.46M
Gross Profit$ 31.89M$ 20.46M
Operating Income$ -235.06M$ -196.94M
EBITDA$ -208.49M$ -163.71M
Net Income$ -203.15M$ -173.77M
Balance Sheet
Cash & Short-Term Investments$ 221.50M$ 393.63M
Total Assets$ 330.18M$ 518.26M
Total Debt$ 68.53M$ 76.97M
Net Debt$ -53.12M$ -99.30M
Total Liabilities$ 953.38M$ 953.35M
Stockholders' Equity$ -615.97M$ -434.52M
Cash Flow
Free Cash Flow$ -204.13M$ -121.20M
Operating Cash Flow$ -200.62M$ -117.75M
Investing Cash Flow$ 116.77M$ -57.73M
Financing Cash Flow$ 28.06M$ 91.33M

Currency in USD

Generate Biomedicines, Inc. Earnings and Revenue History

-240M-120M0120M-900 %-800 %-700 %-600 %EarningsProfit Margin20242025RevenueEarningsProfit Margin

Generate Biomedicines, Inc. Debt to Assets

0400M800M1.2B150 %200 %250 %300 %LiabilitiesDebt to Assets20242025AssetsLiabilitiesDebt to Assets

Generate Biomedicines, Inc. Cash Flow

-300M-200M-100M0100M200M20242025OperatingInvestingFinancing

Generate Biomedicines, Inc. Forecast EPS vs Actual EPS

-1.2-1-0.8-0.6-0.4Q1 26Q2 26EPS EstimateBeatMiss